Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pulse Biosciences, Inc.
* Evaluate lesion clearance of treated facial Sebaceous Hyperplasia lesions using multiple sized treatment tips with microneedles.
* Evaluate lesion clearance of the treated Sebaceous Hyperplasia lesions using multiple energy settings levels at various time points.
* Evaluate skin effects and adverse event rate.
Age
21–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or Female between 18 and 75 years of age
Voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
Understanding of the clinical investigation, agree to cooperate with the investigational procedures and are willing to return for all the required follow-up visits.
Understands that SHs are to be treated in a single treatment session is aware that they may receive a second treatment at their third study visit
Must be able to visit clinic site at 7-, 30-, 60-days post-primary treatment of SH lesion and at 30- and 60-days post-retreatment.
Clinically diagnosis of typical sebaceous hyperplasia.
Minimum of four SH lesions.
Undergo all study procedures including consent for photographs of the treated SH sites.
Agrees to refrain from using all other SH lesion removal products or treatments (topical medication including over-the-counter medications) during the study period.
Active infection or history of infection in designated test area within 90 days prior to first treatment.
Not willing or able to sign the Informed Consent.
Known to be immune-compromised.
Known to be a keloid producer.
Taking blood thinning medications.
Insulin dependent, Type I diabetics.
Allergies to Lidocaine or Lidocaine-like products.
Employed by the sponsor, clinic site, or entity associated with the conduct of the study.
Have any condition or situation which, in the Investigator's opinion, puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study.
Known prior inability to complete required study visits during treatment period.
Use of any other investigational drug, therapy, or device within the past 30 days of enrollment or concurrent participation in another research study.
